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Background: In Benin, the National Malaria Control Programme (NMCP) changed the policy of malaria treatment in
2004 following increasing of failure rate of treatment with chloroquine (CQ) and sulphadoxine-pyrimethamine (SP).
The objective of this study was to determinate the prevalence of Plasmodium falciparum molecular markers that are
associated with resistance to CQ and SP in Benin seven years after the new policy was instituted.
Methods: The study was conducted in southern Benin, a region characterized by a perennial malaria transmission.
Blood samples were collected in 2011 from children presenting with symptomatic and asymptomatic P. falciparum
infections and living in the same area. The prevalence of critical point mutations in the genes of pfcrt (codon 76),
pfmdr1 (codon 86), pfdhfr (codons, 51, 59 and 108) and pfdhps (codons 437, 540) was examined in parasite isolates
by mutation-specific restriction enzyme digestion of nested PCR products.
Results: A high prevalence of parasites carrying point mutations in all studied targets was found: T76: 93.9% [89.8;
96.7], I51: 96.2% [92.7; 98.4], R59: 93, 9% [89.7; 96.7], N108: 97.6% [94.6; 99.2] and G437: 71.4% [64.8; 77.4]. No
mutation was found at codon 540 of the pfdhps gene. The proportion of parasite isolates carrying triple mutation in
the pfdhfr gene IRN (I51, R59 andN108) and quadruple mutation on the combination of pfdhfr/pfdhps IRNG (I51, R59,
N108 and G437) was 91.5% [86.9; 94.9] and 65.7% [58.9; 72.1], respectively. Analysis of mutation in relation to the
clinical status (symptomatic or asymptomatic) and according to age (younger or older than 10 years) showed
similar very high frequencies in each category without significant difference between two groups.
Conclusions: These results suggest a persistence level of resistance of P. falciparum to CQ and SP, seven years after
the recommendation of the change of malaria treatment policy in Benin. The distribution of mutations studied was
neither related to age nor to clinical status.
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In Benin, the anti-malarial treatment policy has long
been based on the use of chloroquine (CQ) and
sulphadoxine-pyrimethamine (SP) as first- and second-
line treatments, respectively. In vivo efficacy studies,
conducted in 2002 by the National Malaria Control
Programme (NMCP) according to the WHO protocol,
had revealed treatment failures rates by region ranging
from 15.0–61.3% with CQ and 3.3–45.9% with SP in
under-fives followed up to 14 days [1]. These studies
were performed in five regions of the country located
in the south (Lokossa), centre (Dassa Zoume, Abomey)
and north (Kouandé, Malanville), with an overall
failure rate of 35.2 for CQ (11.5% and 23.7% early and
late treatment failures respectively) and 22.8% for SP (8.3%
and 24.5% early and late treatment failures respectively)
(unpubl. data from NMCP, Ministry of Health). Based on
these observations, the national anti-malarial drug policy
was changed in 2004 by the official withdrawal of CQ and
SP in the treatment of uncomplicated malaria. However,
SP is still used for the prevention of malaria in pregnancy
through intermittent preventive treatment (IPTp), as
recommended by WHO. The current policy is based on
the use of artemether-lumefantrine (AL)(CoartemW) and
artesunate amodiaquine (ASAQ)(ArsucamW) as first-line
treatment for uncomplicated malaria. It should be noted
that between 2004 and 2005 there was an overlap of treat-
ments with CQ, SP and AL, ASAQ, due to the unavailabil-
ity of the new treatment in some health facilities. In 2005,
Aubouy [2] conducted an in vivo study according to the
WHO protocol over 28 days [3], which showed very high
failure rates (85.7% and 50%), to CQ and SP, respectively.
Since the first reports pointing the decreased efficacy of
anti-malarial drugs on malaria parasites in endemic re-
gions, important investigations led to the discovery of the
involvement of genetic mutations in these parasites con-
ferring resistance [4,5]. Thus, mutations occurring on the
gene pfcrt (T76), and secondarily pfmdr1 (Y86), pfdhps
(G437, E 540, A436), pfdhfr (I51, R59, N108,) have re-
spectively been associated with resistance of P. falciparum
to CQ, and SP [6-9]. Moreover, it has been increasingly
reported in some African settings, that P. falciparum para-
sites again become susceptible to CQ several years after
the withdrawal of the molecule [10,11]. In Benin, no data
on the prevalence of parasite molecular markers of resist-
ance was available before the treatment policy change and
only a limited number of studies of molecular markers of
anti-malarial drug resistance in P. falciparum have been
carried out [12,13]. These studies have focused on genes
pfdhfr and pfdhps and reported high proportion of quad-
ruple mutant parasites (above 80%). Thus, it seemed ap-
propriate to assess the prevalence of different markers of
resistance to CQ and SP in the population of Benin seven
years after the official withdrawal of those drugs in thetreatment of malaria in Benin. The main objective of this
study was to determine the prevalence of P. falciparum
molecular markers that are associated with resistance to
CQ and SP by analysing the point mutations in pfcrt,
pfmdr1, pfdhfr and pfdhps gene using samples from
asymptomatic children and those with uncomplicated
malaria in southern Benin.Methods
Study sites and population
The study was conducted in two highly endemic regions
of southern Benin, including the departments of Littoral
and Ouémé. Southern Benin is characterized by a sub-
equatorial climate and a perennial malaria transmission
with two peaks corresponding to the rainy seasons
(April–July and mid-September–November) [14]. Chil-
dren aged between six months and 15 years, who resided
in the study sites for more than a period of six months
were enrolled from May through August 2011. Asymp-
tomatic children were recruited among the nursery and
primary school pupils in the study area when they
showed a positive thick smear regardless of parasite
density. A census of all nurseries and primary schools in
the study area was initially conducted, from which a
draw of five nurseries and five primary schools was
made. In each school included, all attending students in
all open classes on the day of the survey were involved
in the study. The age ranged from 3 to 5 years in nurser-
ies and 6 to 18 years in primary schools (children over
15 years were screened to evaluate the carriage rate of P.
falciparum in the study area, but were removed from
the sample for molecular analysis). Written informed
consent from the principal and parents were obtained.
For the selection of symptomatic children, WHO proto-
col for in vivo studies was applied to avoid severe mal-
aria or uncomplicated malaria associated with other
diseases. Thus, children visiting the health facilities in the
study area and who met the criteria below were enrolled in
the study: (i) fever (axillary temperature ≥ 37.5°C) or a his-
tory of fever within the past 48 hours, (ii) P. falciparum
mono-infection with parasite density ≥ 1,000 asexual forms
per microlitre, identified by microscopy on blood smears;
(iii) no evidence of a concomitant febrile illness; iv) no
sign/symptoms of severe malaria as defined by WHO [15]
and (v) written informed consent from parents.Sample collection and laboratory procedure
Venous blood from symptomatic children fulfilling the
above criteria was collected systematically on the filter
paper. Samples of asymptomatic children containing
parasites were also stored as spots on filter paper. Thick
and thin blood smears were prepared and were stained
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smears were examined against 500 leucocytes. Parasite
densities were recorded as the number of parasites/μl of
blood, assuming an average leukocyte count of 8,000/μl
of blood. All slides were read in the laboratories of the
health centres, with external quality control performed
on 10% of the negative slides and all positives in the ref-
erence Parasitology Laboratory of the Centre National
Hospitalo-Universitaire in Cotonou. All malaria-infected
patients, based on microscopy results, were treated
according to malaria treatment policy based on ACT:
artemether/lumefantrine.
DNA extraction, PCR- RFLP assay
Parasite DNA was extracted using the Chelex methods
[16] and stored at −20°C until use. The regions of the
pfcrt, pfmdr1, pfdhfr and pfdhps genes containing the
polymorphisms of interest were amplified by nested PCR
described previously [17-19]. The RFLP was performed
by digesting 6 μl (pfcrt and pfmdr1) or 10 μl (pfdhfr and
pfdhps) of PCR products with specific restriction en-
zymes (that varied according to the studied codons) and
buffers obtained from New England Biolabs (Medinova,
Glostrup, Denmark) according to supplier’s specifica-
tions. The pfcrt mutation at codon 76, pfmdr1 mutation
at codon 86, pfdhfr mutations at codons 51, 59, 108, and
pfdhps mutations at codons 437 and 540, were charac-
terized. Five laboratory clones (3D7, FCR3, HB3, D10
and Dd2) used as a standard positive controls and nega-
tive controls (without DNA) were amplified and also
digested with the samples. The digested products were
visualized by electrophoresis on 1.5% agarose gels
containing ethidium bromide. Gels were recorded by
digital photography. Four samples of each series were
randomly selected and tested repeatedly to check the re-
producibility of the technique. Enzymes and control





Number and size of bands
obtained (bp)
pfdhfr : Nested PCR product size : 594
Alu I S108/3D7 2bands : 280+ 314
Tsp 509 I N51/3D7 FRC3 2 bands : 125+ 150
Xmn I C59/3D7, FCR3 2bands : 250+ 344
pfdhps : Nested PCR product size : 711
Ava II A437/FCR3 1band : 711
Fok I K540/3D7, Dd2, FCR3 1band : 711
pfcrt : Nested PCR product size : 145
Apo I K76/3D7, HB3 2 bands : 99 + 46
pfmdr1 : Nested PCR product size : 521
AFI III N86/3D7, HB3 1 band : 521mutant or wild-type strains are shown in Table 1. Con-
trol strains were used for each analysis and mutations
were determined to be present or absent on the basis of
the presence or absence of the expected bands on the
gel. Markers of 100 bp (Pharmacia Biotech) were used to
size the bands. Each codon was characterized as wild-
type (no mutation present), pure mutant (only mutant
genotypes detected). Cases of mixed infection (wild type
and mutant) were categorized as mutant throughout the
analysis. All molecular analyses were performed in the
Molecular Biology Laboratory of Center for integrated
malaria control (CLIP).
Data analysis
The data were entered in the software Reversion 2.12.0
(R Foundation for Statistical Computing, Vienna,
Austria). The frequency of a particular mutant was cal-
culated as the proportion of the specific mutant samples
among the total number of samples successfully analysed
for this mutation. Similarly, the frequencies of double,
triple and quadruple mutants were determined as the
proportion of subjects with two, three and four muta-
tions among the total numbers of samples tested for the
each. To investigate the relationship between the muta-
tion and age, children were segregated into two categor-
ies: children below and above 10 years of age. The
reason for this division is that recent intensification of
malaria control activities in the country, such as the
widespread distribution and use of insecticide-treated
nets, large-scale indoor residual spraying is likely to im-
pact the acquisition of immunity, usually achieved at
about five years of age in endemic areas [20]. Wilcoxon
test and Student test were used to compare the distribu-
tion of age according to the clinical status and distribu-
tion of the parasite density respectively. The chi-square
test or Fisher’s exact test was used for proportion
comparisons. The significance level (P < 0.05) was usedents obtained by codon
Mutant alleles/control
used
Number and size of bands
obtained (bp)
N108 or T108 HB3, Dd2 1 band : 594
I51/Dd2 2bands : 125+ 250.
R59/Dd2 2bands : 250+ 320
G437/3D7, Dd2 1band : 650
E540/D10 2bands : 311 + 400pb
T76/Dd2 1 band : 145
Y86/FCR3 2 bands : 346 + 175
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and age.
Ethical approval
This study was approved by Ethical Committee of the
Faculté des Sciences de la Santé, Cotonou, Benin.
Results
Characteristics of the study population
A total of 2,249 asymptomatic children were screened
for malaria parasitaemia; 208 samples were found posi-
tive for P. falciparum and were collected and stored as
spots on filter paper. The carriage rate of P. falciparum
was 9.2%. From these positive cases, 143 samples were
selected for molecular analysis (after the withdrawal of
children above 15 years age). A total of 73 samples of
symptomatic subjects were collected and analysed. Thus
a total of 216 samples were analysed for point mutations.
The characteristics of subjects enrolled are shown in
Table 2. For each target studied, the number of isolates
actually analysed depended on the success of PCR amp-
lification and were 213 for pfcrt, 212 for pfmdr1and
pfdhfr, and 210 for pfdhps. Retested samples to check
the reproducibility results were consistent with those
found initially.
Prevalence of pfcrt and pfmdr1, alleles and mutations
The mutant allele T76 of pfcrt gene was present in 92%
(196/213) of samples from patients that were analysed
for this mutation. In contrast, only 28.3% (60/212) of
samples analysed carried mutation type allele Y86 of
pfmdr1. 42.9% carried the wild-type allele (N86), and
28.8% carried a mixture of the wild type and the mutant
allele (N86Y86) (Figure 1).
The T76 mutation was present in 93.9% (200/213)
[89.8; 96.7], which was higher in that population than
Y86: 57.1% (121/212) [50.1; 63.8] and the double muta-
tion T76Y86: 55.2% (117/212) [48.5; 62.3] (P < 0.001)
(Table 3).Table 2 Characteristics of the study population
Sy
Number (%) 7
Age (years) Mean (SD)
Median (IQR)
Children below 10 years n (%) 5
M/F ratio 3
Parasitaemia Geometric mean 95% CI
[507
Median (IQR) 7000
w: Wilcoxon’s test; b: Chi 2 test t: Student test.Prevalence of pfdhps and pfdhfr alleles and mutations
Pfdhps: a mixture of the wild type and the mutant allele
(A437G437) was more represented with codon 437:
57.1% (120/210), whereas all samples carried wild type
allele (K540) with codon 540 (Figure 2). Mutation of
codon 437 (G437) was high with 71.4% (150/210) [64.8;
77.4] while no mutation was found with the codon 540
(E540) in the study population (Table 3).
Pfdhfr: mutated alleles were more represented for
codon 51 (I51), codon 59 (R59) and codon 108 (N108),
respectively, 96.2% (204/212), 93.9% (199/212), and
95.8% (203/212). No mixture of alleles was found with
codon 51 and codon 59, but in a very small proportion
with codon 108 (S108N108): 1.9% (4/212) (Figure 3).
The proportion of single, triple and quadruple muta-
tion was very high in the study population: I51: 96.2%
(204/210) [92.7; 98.4], R59: 93.9% (199/212) [89.7; 96.7],
N108: 97.6% (207/212) [94.6; 99.2], Pfdhfr triple mutant
IRN (I51, R59 and N108): 91.5% (194/212) [86.9; 94.9],
Pfdhfr/Pfdhps quadruple mutant IRNG (Pfdhfr I51, R59,
N108, and Pfdhps G437): 65.7% (138/210) [58.9; 72.1]
(Table 3).Mutation and clinical status and age
According clinical group, Y86 and double mutation
T76Y86 were more represented in asymptomatic group.
P = 0.03. Otherwise, there was no significant difference
between prevalence of single, double, triple or quadruple
mutation and clinical status (Table 3). When the data
were analysed by age categories similar frequencies of
single, triple and quadruple mutant parasite were found
in children younger than 10 years and in older children,
regardless of the clinical status. The purpose here was to
see if the distribution of mutant parasites could be af-
fected by age and therefore probably by the gradual ac-
quisition of immunity. However, a tendency towards
elevation of Y86 and double mutation T76Y86 rate
among symptomatic children less than 10 years was





3 (33.8%) 143 (66.2%)
7.8 (3.0) 8.3 (2.5)
8 (7–9) 9 (8–10) 0.09w
6 (76.7%) 82 (57.3%) 0.008b
9/34; 1.15 73/70; 1.04 0.85b
6822.58 656.69 <0.001t
2.29; 9176.86] [474.74; 908.36]
(2400–15000) 1000 (150–2520) <0.001w
Figure 1 Prevalence of pfcrt and pfmdr alleles.
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The main objective of this study was to evaluate the
prevalence in Benin of P. falciparum resistance markers
to CQ and SP, two conventional anti-malarials that have
been used for a long time. This study was justified by
the need of surveillance of P. falciparum resistance to
anti-malarials drugs in Benin through well-characterized
molecular markers of resistance to contribute to the
monitoring in the subregion. This monitoring is
intended on the one hand to watch for a possible return
of sensitivity of P. falciparum to CQ and secondly, to de-
scribe the current patterns of molecular markers associ-
ated with parasite resistance to SP, the latter still used as
a preventive treatment of malaria in pregnant women.
This work was carried out on parasites obtained from
two distinct clinical groups of children, to investigate a
possible relationship between molecular markers and
clinical status. Mutation at codon 164 of pfdhfr gene has
not been studied because several studies have noted theTable 3 Prevalence of molecular markers associated with P. fa
asymptomatic children
Molecular marker Population n (%) Sympto
T76 (n = 213) 200 (93.9%)* 68/72 94
Y86 (n = 212) 121 (57.1%) 29/71 (4
T76Y86 (n = 212) 117 (55.2%) 28/71 (3
G437 (n = 210) 150 (71.4%) 48/73 (6
E540 (n = 210) 0% 0%
I51 (n = 212) 204 (96.2%) 69/73 (9
R59 (n = 212) 199 (93.9%) 69/73 (9
N108 (n = 212) 207 (97.6%) 71/73 (9
IRN1 (n = 212) 194 (91.5%) 67/73 (9
IRNG2 (n = 210) 138 (65.7%) 44/73 (6
1 pfdhfr triple mutants (I51, R59, and N108).
2 pfdhfr/pfdhps quadruple mutants (pfdhfr I51, R59, N108 and pfdhps G437).
*p < 0.001 of Chi 2 test (comparison between T76 and Y86, T76 and T76Y86).
a p-value of fisher test.
b p-value of Chi 2 test.absence or rarity of this mutation in African isolates
[13,21-24].
High rates of single, double, triple or quadruple muta-
tion observed in this study reflect the current level of
sensitivity of P. falciparum to CQ and SP in Benin,
which is still expected to be low although the two drugs
were officially withdrawn from curative treatment of un-
complicated malaria in 2004. These high rates of mutant
parasites had been previously found by other authors
[23,25-28]. The fact that the frequency of mutations at
codon site 437 of pfdhps is lower than those observed
on the pfdhfr gene confirms that the mutations associ-
ated with parasite resistance to SP appeared earlier on
the pfdhfr than those affecting the pfdhps [29,30].
Similar to other reports from the sub-region [31,32],
the parasites harbouring the mutation at codon 540E
were not found in Benin. Regarding the pfcrt gene, ana-
lysis of the T76 mutation (93.9%) in isolates from Benin
showed a high prevalence of parasites carrying thislciparum resistance to CQ and SP in symptomatic and
matic n (%) Asymptomatic n (%) p-value
.4%) 132/141 (93.6%) 1a
0.8%) 92/141 (65.2%) 0.03b
9.4%) 89/140 (63.6%) 0.03b
5.8%) 102/137 (74.5%) 0.42b
0%
4.5%) 135/139 (97.1%) 0.45a
4.5%) 130/139 (93.5%) 1a
7.3%) 136/139 (97.8%) 0.72a
1.8%) 127/139 (91.4%) 0.61b
0.3%) 94/137 (68.6%) 0.15b
Figure 2 Prevalence of pfdhps alleles.
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sal of the prevalence of mutant T76 a few years after the
withdrawal of CQ [10,11], it is clear that this has not
been the case in Benin. Self-medication with fake medi-
cines especially with regard to CQ (despite its formal
withdrawal from the treatment policy of malaria) could
be a leading cause for maintaining this high prevalence
of T76 mutant parasites as a result of continued and fre-
quent use of CQ [33] involving either insufficient doses
or too short a duration of administration. It is a com-
mon practice in the south of the country characterized
by large markets (with neighbouring Nigeria) where il-
legitimate distribution of fake drugs is common [2,34].
This could also be marginally explained by a possible
cross-resistance shared between CQ and AQ [35,36],
since AQ is present in the ASAQ combination currently
used for malaria management in Benin. WHO in vivo
drug efficacy studies conducted in 2008 with thisFigure 3 Prevalence of pfdhfr alleles.combination in two localities of the country noted an
adequate clinical and parasitological response (ACPR) of
100% and 76.6% respectively without PCR correction.
The second locality (Dassa Zoume) with a decrease of
ACPR (23.44% of late parasitological failure) had posted
38.8% of late parasitological failure in 2002 during
in vivo drug efficacy studies with CQ (unpublished data
from Ministry of Health, Benin).
Thus, the re-emergence of sensitive parasite strains
after the withdrawal of CQ depends not only on the time
elapsed since the withdrawal of the treatment, but also
on the speed of replacement and implementation of the
new drugs, to allow the cessation of use and consump-
tion of drugs replaced. It is important that the health au-
thorities of the country ensure the effective withdrawal
of CQ by emphasizing the education about the risks of
self-medication and implementing control methods
against the entry of fake medicines. The results obtained
Table 4 Prevalence of mutations conferring resistance to




< 10 ans ≥ 10 ans < 10 ans ≥ 10 ans
T 76 53 (94.6%) 15 (93.8%) 74 (91.4%) 58 (96.7%)
Y86 25 (45.5%) 4 (25%)* 49 (60.5%) 43 (71.7%)
T76 + Y86 24 (43.6%) 4 (25%)** 47 (58.8%) 42 (70%)
G437 36 (64.3%) 12 (70.6%) 54 (68.4%) 48 (82.8%)
E540 0% 0% 0% 0%
I51 52 (92.9%) 17 (100) 77 (96.2%) 58 (98.3%)
R59 53 (94.6%) 16 (94.1%) 77 (96.2%) 53 (89.8%)
N108 54 (96.4%) 17 (100) 78 (97.5%) 58 (98.3%)
IRN1 51 (91.1%) 16 (94.1%) 76 (95%) 51 (86.4%)
IRNG2 33 (58.9%) 11 (64.7%) 52 (65.8%) 42 (72.4%)
1pfdhfr triple mutants: (I51, R59, and N108).
2pfdhfr/pfdhps quadruple mutants: (pfdhfr I51, R59, N108 and pfdhps G437).
*p = 0.16 (fisher test).
**p = 0.24 (fisher test).
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in China by Zang et al. [37], but is in contrast to those
reported by Kamugisha et al. in Tanzania [38] and
Raman et al. in Mozambique [39].
Regarding SP, it should be noted that the use of other
sulpha drugs, such as trimethoprim-sulphametoxazole
(co-trimoxazole) often prescribed for bacterial infections
in children but also in prevention and treatment of
opportunistic infections in persons living with HIV, con-
tribute in maintaining drug pressure on malaria para-
sites. The use of SP in intermittent preventive treatment
in pregnant women (IPTp) since its withdrawal from the
treatment of uncomplicated malaria may also explain
the maintain of the selective pressure on SP targets as
shown in the study conducted by Bertin et al. in Benin
and Pearce et al. in Tanzania [13,40]. Similarly to what
has been reported by other authors [17,27], this study
shows that regardless of the gene, mutations are not as-
sociated with the clinical status of children. On the other
hand, to determine whether immunity contributed to
the ability to clear infections by parasites carrying resist-
ance, the proportion of infections by parasites carrying
different mutations compared between children younger
than 10 years and older children suggests that age does
not influence the distribution and carriage of resistant
parasites whatever the clinical status and type of
mutation.
Conclusions
This study showed high prevalence of pfcrt76 and quad-
ruple phdhfr/pfdhps mutants parasites (triple mutant
pfdhfr + single 437 pfdhps mutant) confirming the per-
sistence of parasite resistance to CQ and SP in Benin
several years after officially withdrawal of these twodrugs in the treatment of uncomplicated malaria. Clin-
ical status and age do not seem to influence the fre-
quency of individual mutants or the distribution of the
triple and quadruple mutant parasites. This study has
generated data which will be useful in monitoring the
dynamics of drug resistant malaria parasites in Benin
and in the sub-region.
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